Laurus Labs Ltd
30 Oct 2026 12:00 AM
Laurus Labs Ltd consolidated sales up 8.89% on year in Q3FY2026, net profit saw a strong growth of 20.65%,
Laurus Labs Ltd share price gained 2.75% to Rs 2245.0 after the company`s net profit surged by 20.65% to Rs 436.74 crore, while revenue from operations slightly gained 8.89% to Rs 2206.37 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.44%. It has improved by 5.74% over last one week and gained upto 0.60% in last one month while the market capitalization of Laurus Labs Ltd has increased 13.73% and 23.62% in the same period respectively.
Profit before tax (PBT) of Laurus Labs Ltd stood at Rs 591.82 crore in Q3 FY26, rallying 119.41% year-on-year, and surging by 22.95% quarter-on-quarter. EBITDA came in at Rs 737 crore, jumping 95.93% YoY and expanding by 17.20% sequentially.
Total expenses inched up 4.73% to Rs 1583.46 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 900.69 crore, increasing 14.63% YoY, while employee benefits expense was at Rs 265.71 crore, ticking higher by 2.71% YoY.
For the TTM ended FY26, revenue from operations surged 22.67% to Rs 6812.9 crore, while net profit soared by 151.08% to Rs 889.85 crore, compared to previous TTM. EBITDA jumped by 102914% to Rs 1722.76 crore, and PBT jumped 144.04% to Rs 1181.88 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 1623.5 crore in FY26, as against Rs 601.65 crore in FY25.
Laurus Labs Ltd rallied 133.49% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 12.76% during the same period.
Laurus Labs Ltd
29 Oct 2026 12:00 AM
Laurus Labs Ltd consolidated sales up 8.89% on year in Q3FY2026, net profit surged by 20.65%,
Laurus Labs Ltd share price ticked higher by 2.11% to Rs 2184.95 after the company`s net profit saw a strong growth of 20.65% to Rs 436.74 crore, while revenue from operations improved marginally 8.89% to Rs 2206.37 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.24%. It has improved by 3.87% over last one week and gained upto 0.06% in last one month while the market capitalization of Laurus Labs Ltd has inched up 9.36% and 20.31% in the same period respectively.
Profit before tax (PBT) of Laurus Labs Ltd stood at Rs 591.82 crore in Q3 FY26, jumping 119.41% year-on-year, and rallying 22.95% quarter-on-quarter. EBITDA came in at Rs 737 crore, expanding by 95.93% YoY and surging by 17.20% sequentially.
Total expenses saw a slight increase of 4.73% to Rs 1583.46 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 900.69 crore, advancing by 14.63% YoY, while employee benefits expense was at Rs 265.71 crore, easing 2.71% YoY.
For the TTM ended FY26, revenue from operations jumped by 22.67% to Rs 6812.9 crore, while net profit jumped 151.08% to Rs 889.85 crore, compared to previous TTM. EBITDA soared by 102914% to Rs 1722.76 crore, and PBT witnessed a strong rise of 144.04% to Rs 1181.88 crore compared to previous TTM.
The company`s consolidated net cash flow from operating activities stood at Rs 1623.5 crore in FY26, as against Rs 601.65 crore in FY25.
Laurus Labs Ltd rallied 127.68% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 13.45% during the same period.
Laurus Labs Ltd
29 Oct 2026 12:00 AM
Laurus Labs’ board approved an interim dividend of Re. 1.00 per equity share,
Laurus Labs Limited announced that its board of directors approved an interim dividend of Re. 1.00, or 50%, per equity share of Rs 2 each for the financial year ending March 31, 2027, with November 6, 2026, set as the record date and payment expected on or after November 19, 2026.
Laurus Labs Ltd
29 Oct 2026 12:00 AM
Laurus Labs to acquire 52% stake in SI & C Resins for Rs 32.50 crore,
Laurus Labs Limited announced that its board approved the acquisition of 52% of the share capital of SI & C Resins Private Limited for a pre-money valuation of Rs 30 crore, involving a total investment of Rs 32.50 crore through the primary acquisition of 10,833 equity shares. SI & C Resins, incorporated in July 2026, specializes in manufacturing and supplying polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries, and the acquisition will be completed during the current financial year, subject to customary closing conditions.
Laurus Labs Ltd
29 Oct 2026 12:00 AM
Laurus Labs to acquire 60% stake in Canada’s Galenvs Sciences for USD 3.75 million,
Laurus Labs Limited announced that its board of directors approved the acquisition of 60% of the share capital of Galenvs Sciences Inc., a Canada-based contract research and development organization (CRO/CDMO), for a pre-money valuation of USD 3.50 million. The company will invest a total of USD 3.75 million, comprising a primary infusion of USD 2.75 million and a secondary acquisition of USD 1.00 million, with Galenvs operating as a subsidiary and its wholly-owned subsidiary, Galenvs Solutions Inc., becoming a step-down subsidiary of Laurus Labs.
Subscribe for our
newsletter
newsletter
HSL Mobile App